{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:10:45Z","timestamp":1789999845435,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hormone-dependent cancers, particularly estrogen receptor-positive breast cancer and androgen receptor-driven prostate cancer, contribute substantially to global cancer-related morbidity and mortality. Endocrine therapy has long been the mainstay of treatment for these tumors because of its specific mechanism and good safety profile. The long-term success of common hormone-based treatments is often undermined by resistance, both intrinsic and acquired, disease recurrence, and the activation of compensatory pathways that tumor cells have adapted to. To overcome these challenges, it has been necessary to develop high-quality hormone-based biopharmaceuticals that target the molecular level, enhance pharmacokinetics, and apply precision medicine strategies. The goal of this literature review is to provide an update on progress in hormone-based biopharmaceuticals for cancer management, with a particular focus on preventing endocrine resistance in hormone-dependent cancers. Among the treatments mentioned in the review, most are oral selective estrogen receptor degraders (SERDs) for ER-positive breast cancer, oral gonadotropin-releasing hormone antagonists for prostate cancer, genomically guided combination therapy that integrates inhibitors of the CDK4\/6 and PI3K\/AKT\/mTOR signaling pathways, and next-generation androgen receptor (AR) degraders based on proteolysis-targeting chimera (PROTAC) technology. There is new evidence that these biopharmaceutical methods may be able to treat patients better over longer periods. For those who are less responsive, these approaches are even more effective when paired with proper biopharmaceutical methods, as in the case of hormone therapy. While targeted protein degradation and biomarker-driven combination therapies are repositioning drug development away from receptor blockade, the latter remains the mainstay of treatment. However, these developments do not eliminate concerns related to long-term safety, cost-effectiveness, appropriate patient selection, and resistance to novel agents. The path for hormone-based biopharmaceuticals in personalized cancer therapy requires continuous translational research and clinical validation to determine the best place.<\/jats:p>","DOI":"10.1186\/s43046-026-00411-5","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:19:45Z","timestamp":1789996785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent advances in hormone-based biopharmaceuticals for cancer therapy"],"prefix":"10.1186","volume":"38","author":[{"given":"Syahmi Nuqman","family":"Sarifulnazwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Alia Fatihah","family":"Mohd Tajuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siti Nur Nadhirah","family":"Mohd Nasaruddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Malihah Imtiyaz","family":"Muhammad Mukmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engku Shifaa Nur Sahira","family":"Engku Abdul Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Taher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5345-1150","authenticated-orcid":false,"given":"Deny","family":"Susanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaidi","family":"Khotib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3455-8443","authenticated-orcid":false,"given":"Md","family":"Faiyazuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7087-2873","authenticated-orcid":false,"given":"Riyanto Teguh","family":"Widodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4708-4603","authenticated-orcid":false,"given":"Muhammad Salahuddin","family":"Haris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendra","family":"Budiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"411_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s12672-016-0259-0","volume":"7","author":"CP Capper","year":"2016","unstructured":"Capper CP, Rae JM, Auchus RJ. The metabolism, analysis, and targeting of steroid hormones in breast and prostate cancer. Horm Cancer. 2016;7:149\u201364. https:\/\/doi.org\/10.1007\/s12672-016-0259-0.","journal-title":"Horm Cancer"},{"key":"411_CR2","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.31557\/APJCP.2025.26.9.3377","volume":"26","author":"SA Kristina","year":"2025","unstructured":"Kristina SA, Krisnadewi K, Trung V, Ramadhani A, Sari Verdiana A, Daffa Aryasatya M. Cancer burden across the South East Asia Nation (ASEAN) in 2022. Asian Pac J Cancer Prev. 2025;26:3377\u201388. https:\/\/doi.org\/10.31557\/APJCP.2025.26.9.3377.","journal-title":"Asian Pac J Cancer Prev"},{"key":"411_CR3","doi-asserted-by":"publisher","unstructured":"Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2021:CD002747 (2003). https:\/\/doi.org\/10.1002\/14651858.CD002747.","DOI":"10.1002\/14651858.CD002747"},{"key":"411_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/978-981-16-4546-4_21","volume-title":"Breast Cancer","author":"S Kumar","year":"2022","unstructured":"Kumar S, Gupta S, Maurya AP, Singh R, Nigam S. Hormonal and targeted treatments in breast cancer. In: Sharma SC, Mazumdar A, Kaushik R, editors. Breast Cancer. Singapore: Springer Nature Singapore; 2022. pp. 443\u201363."},{"key":"411_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/CMAR.S98249","volume":"8","author":"WJ Gradishar","year":"2016","unstructured":"Gradishar WJ. Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Cancer Manag Res. 2016;8:85\u201394. https:\/\/doi.org\/10.2147\/CMAR.S98249.","journal-title":"Cancer Manag Res"},{"key":"411_CR6","doi-asserted-by":"publisher","first-page":"1564642","DOI":"10.3389\/or.2025.1564642","volume":"19","author":"N Kim","year":"2025","unstructured":"Kim N, Lukong KE. Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action. Oncol Rev. 2025;19:1564642. https:\/\/doi.org\/10.3389\/or.2025.1564642.","journal-title":"Oncol Rev"},{"key":"411_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3390\/cancers16030619","volume":"16","author":"N Neupane","year":"2024","unstructured":"Neupane N, Bawek S, Gurusinghe S, Ghaffary EM, Mirmosayyeb O, Thapa S, Falkson C, O\u2019Regan R, Dhakal A. Oral SERD, a novel endocrine therapy for estrogen receptor-positive breast cancer. Cancers. 2024;16:619. https:\/\/doi.org\/10.3390\/cancers16030619.","journal-title":"Cancers"},{"key":"411_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1210\/en.2018-01095","volume":"160","author":"SW Fanning","year":"2019","unstructured":"Fanning SW, Greene GL. Next-generation ER\u03b1 inhibitors for endocrine-resistant ER+ breast cancer. Endocrinology. 2019;160:759\u201369. https:\/\/doi.org\/10.1210\/en.2018-01095.","journal-title":"Endocrinology"},{"key":"411_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/CCO.0000000000001085","volume":"36","author":"L Ascione","year":"2024","unstructured":"Ascione L, Castellano G, Curigliano G, Zagami P. Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives. Curr Opin Oncol. 2024;36:465\u201373. https:\/\/doi.org\/10.1097\/CCO.0000000000001085.","journal-title":"Curr Opin Oncol"},{"key":"411_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nrm.2016.122","volume":"17","author":"ER Levin","year":"2016","unstructured":"Levin ER, Hammes SR. Nuclear receptors outside the nucleus: extranuclear signalling by steroid receptors. Nat Rev Mol Cell Biol. 2016;17:783\u201397. https:\/\/doi.org\/10.1038\/nrm.2016.122.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"411_CR11","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1093\/emboj\/19.20.5406","volume":"19","author":"A Migliaccio","year":"2000","unstructured":"Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C, Auricchio F. Steroid-induced androgen receptor\u2013oestradiol receptor \u03b2\u2013Src complex triggers prostate cancer cell proliferation. EMBO J. 2000;19:5406\u201317. https:\/\/doi.org\/10.1093\/emboj\/19.20.5406.","journal-title":"EMBO J"},{"key":"411_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1126\/science.1147674","volume":"319","author":"B Perillo","year":"2008","unstructured":"Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A, Chiariotti L, Malorni A, Abbondanza C, Avvedimento EV. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science. 2008;319:202\u20136. https:\/\/doi.org\/10.1126\/science.1147674.","journal-title":"Science"},{"key":"411_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","volume":"62","author":"CK Osborne","year":"2011","unstructured":"Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233\u201347. https:\/\/doi.org\/10.1146\/annurev-med-070909-182917.","journal-title":"Annu Rev Med"},{"key":"411_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc.2016.30","volume":"16","author":"A Clocchiatti","year":"2016","unstructured":"Clocchiatti A, Cora E, Zhang Y, Dotto GP. Sexual dimorphism in cancer. Nat Rev Cancer. 2016;16:330\u20139. https:\/\/doi.org\/10.1038\/nrc.2016.30.","journal-title":"Nat Rev Cancer"},{"key":"411_CR15","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626\u201338. https:\/\/doi.org\/10.1038\/nri.2016.90.","journal-title":"Nat Rev Immunol"},{"key":"411_CR16","first-page":"663","volume":"13","author":"KC Kadakia","year":"2015","unstructured":"Kadakia KC, Henry NL. Adjuvant endocrine therapy in premenopausal women with breast cancer. Clin Adv Hematol Oncol. 2015;13:663\u201372.","journal-title":"Clin Adv Hematol Oncol"},{"key":"411_CR17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-med-052423-122001","volume":"76","author":"N Pathak","year":"2025","unstructured":"Pathak N, Oliveira M. New oral selective estrogen receptor degraders redefine management of estrogen receptor-positive breast cancer. Annu Rev Med. 2025;76:243\u201355. https:\/\/doi.org\/10.1146\/annurev-med-052423-122001.","journal-title":"Annu Rev Med"},{"key":"411_CR18","doi-asserted-by":"publisher","first-page":"176424","DOI":"10.1016\/j.ejphar.2024.176424","volume":"969","author":"G Guglielmi","year":"2024","unstructured":"Guglielmi G, Del Re M, Gol LS, Bengala C, Danesi R, Fogli S. Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer. Eur J Pharmacol. 2024;969:176424. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176424.","journal-title":"Eur J Pharmacol"},{"key":"411_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41523-022-00483-1","volume":"8","author":"S Pancholi","year":"2022","unstructured":"Pancholi S, Simigdala N, Ribas R, Schuster E, Leal MF, Nikitorowicz-Buniak J, Rega C, Bihani T, Patel H, Johnston SR, Dowsett M, Martin L-A. Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer. npj Breast Cancer. 2022;8:125. https:\/\/doi.org\/10.1038\/s41523-022-00483-1.","journal-title":"npj Breast Cancer"},{"key":"411_CR20","unstructured":"Bardia A et al. Results of the prespecified interim analysis of the global, randomized lidERA Breast Cancer trial (NCT04961996). Presented at the San Antonio Breast Cancer Symposium. : 2025; 9\u201312 December 2025; San Antonio, TX."},{"key":"411_CR21","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim S-B, Tokunaga E, et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2025;392:1189\u2013202. https:\/\/doi.org\/10.1056\/NEJMoa2410858.","journal-title":"N Engl J Med"},{"key":"411_CR22","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1158\/0008-5472.CAN-23-0694","volume":"83","author":"M Lawson","year":"2023","unstructured":"Lawson M, Cureton N, Ros S, Cheraghchi-Bashi A, Urosevic J, D\u2019Arcy S, Delpuech O, DuPont M, Fisher DI, Gangl ET, Lewis H, Trueman D, Wali N, Williamson SC, Moss J, Montaudon E, Derrien H, Marangoni E, Miragaia RJ, Gagrica S, Morentin-Gutierrez P, Moss TA, Maglennon G, Sutton D, Polanski R, Rosen A, Cairns J, Zhang P, S\u00e1nchez-Guix\u00e9 M, Serra V, Critchlow SE, Scott JS, Lindemann JPO, Barry ST, Klinowska T, Morrow CJ, Carnevalli LS. The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4\/6 inhibitor resistance. Cancer Res. 2023;83:3989\u20134004. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0694.","journal-title":"Cancer Res"},{"key":"411_CR23","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2217\/fon-2022-1196","volume":"19","author":"N Turner","year":"2023","unstructured":"Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, Iwata H, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, McClain S, Bidard F-C. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023;19:559\u201373. https:\/\/doi.org\/10.2217\/fon-2022-1196.","journal-title":"Future Oncol"},{"key":"411_CR24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"F-C Bidard","year":"2025","unstructured":"Bidard F-C, Mayer EL, Park YH, Janni W, Ma CX, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N Engl J Med. 2025;393:569\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2502929.","journal-title":"N Engl J Med"},{"key":"411_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41571-025-01062-6","volume":"22","author":"P Neven","year":"2025","unstructured":"Neven P, Han SN. PROTAC SERD vepdegestrant outperforms fulvestrant for advanced-stage ER-positive\/HER2-negative breast cancer harbouring acquired ESR1 mutations. Nat Rev Clin Oncol. 2025;22:709\u201310. https:\/\/doi.org\/10.1038\/s41571-025-01062-6.","journal-title":"Nat Rev Clin Oncol"},{"key":"411_CR26","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27:5730. https:\/\/doi.org\/10.3390\/molecules27175730.","journal-title":"Molecules"},{"key":"411_CR27","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.eururo.2006.06.034","volume":"50","author":"A Morgentaler","year":"2006","unstructured":"Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006;50:935\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2006.06.034.","journal-title":"Eur Urol"},{"key":"411_CR28","unstructured":"National Cancer Institute. Hormone therapy for prostate cancer fact sheet. https:\/\/www.cancer.gov\/types\/prostate\/prostate-hormone-therapy-fact-sheet."},{"key":"411_CR29","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2147\/DDDT.S291369","volume":"15","author":"Y-F Liu","year":"2021","unstructured":"Liu Y-F, Fu S-Q, Yan Y-C, Gong B-B, Xie W-J, Yang X-R, Sun T, Ma M. Progress in clinical research on gonadotropin-releasing hormone receptor antagonists for the treatment of prostate cancer. Drug Des Devel Ther. 2021;15:639\u201349. https:\/\/doi.org\/10.2147\/DDDT.S291369.","journal-title":"Drug Des Devel Ther"},{"key":"411_CR30","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.eururo.2007.12.021","volume":"53","author":"A Stangelberger","year":"2008","unstructured":"Stangelberger A, Schally AV, Djavan B. New treatment approaches for prostate cancer based on peptide analogues. Eur Urol. 2008;53:890\u2013900. https:\/\/doi.org\/10.1016\/j.eururo.2007.12.021.","journal-title":"Eur Urol"},{"key":"411_CR31","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1021\/jm701249f","volume":"51","author":"SF Betz","year":"2008","unstructured":"Betz SF, Zhu Y-F, Chen C, Struthers RS. Non-peptide gonadotropin-releasing hormone receptor antagonists. J Med Chem. 2008;51:3331\u201348. https:\/\/doi.org\/10.1021\/jm701249f.","journal-title":"J Med Chem"},{"key":"411_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0015-0282(01)01972-0","volume":"76","author":"Z Blumenfeld","year":"2001","unstructured":"Blumenfeld Z. Gonadotropin-releasing hormone antagonists instead of agonists: a change for the better? Fertil Steril. 2001;76:443\u20134. https:\/\/doi.org\/10.1016\/S0015-0282(01)01972-0.","journal-title":"Fertil Steril"},{"key":"411_CR33","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/S0140-6736(01)06797-6","volume":"358","author":"JA Huirne","year":"2001","unstructured":"Huirne JA, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet. 2001;358:1793\u2013803. https:\/\/doi.org\/10.1016\/S0140-6736(01)06797-6.","journal-title":"Lancet"},{"key":"411_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1756287212461048","volume":"5","author":"ND Shore","year":"2013","unstructured":"Shore ND. Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol. 2013;5:11\u201324. https:\/\/doi.org\/10.1177\/1756287212461048.","journal-title":"Ther Adv Urol"},{"key":"411_CR35","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.2147\/DDDT.S373546","volume":"17","author":"T Tatenuma","year":"2023","unstructured":"Tatenuma T, Miyamoto H. Profile of relugolix in the management of advanced hormone-sensitive prostate cancer: design, development, and place in therapy. Drug Des Devel Ther. 2023;17:2325\u201333. https:\/\/doi.org\/10.2147\/DDDT.S373546.","journal-title":"Drug Des Devel Ther"},{"key":"411_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1358\/dof.2019.44.2.2927590","volume":"44","author":"A Elsharoud","year":"2019","unstructured":"Elsharoud A, Ali M, Al-Hendy A. Relugolix. GnRH (LHRH) receptor antagonist, treatment of uterine fibroids, treatment of endometriosis-related pain, treatment of prostate cancer. Drugs Fut. 2019;44:131. https:\/\/doi.org\/10.1358\/dof.2019.44.2.2927590.","journal-title":"Drugs Fut"},{"key":"411_CR37","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.japh.2022.12.019","volume":"63","author":"OA Adekunle","year":"2023","unstructured":"Adekunle OA, Seoane-Vazquez E, Brown LM. Cost-effectiveness analysis of androgen deprivation therapy with relugolix for the treatment of advanced prostate cancer. J Am Pharm Assoc. 2023;63:817\u2013e8243. https:\/\/doi.org\/10.1016\/j.japh.2022.12.019.","journal-title":"J Am Pharm Assoc"},{"key":"411_CR38","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/RRU.S388265","volume":"17","author":"A Quistini","year":"2025","unstructured":"Quistini A, Chierigo F, Fallara G, Depalma M, Tozzi M, Maggi M, Jannello LMI, Pellegrino F, Mantica G, Terracciano D, Papalia R, Crocetto F, Damiano R, Bianchi R, Rocco BM, Ferro M. Androgen receptor signalling in prostate cancer: mechanisms of resistance to endocrine therapies. Res Rep Urol. 2025;17:211\u201323. https:\/\/doi.org\/10.2147\/RRU.S388265.","journal-title":"Res Rep Urol"},{"key":"411_CR39","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/cancers16030663","volume":"16","author":"Q-H Chen","year":"2024","unstructured":"Chen Q-H, Munoz E, Ashong D. Insight into recent advances in degrading androgen receptor for castration-resistant prostate cancer. Cancers. 2024;16:663. https:\/\/doi.org\/10.3390\/cancers16030663.","journal-title":"Cancers"},{"key":"411_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neo.2019.12.003","volume":"22","author":"S Kregel","year":"2020","unstructured":"Kregel S, Wang C, Han X, Xiao L, Fernandez-Salas E, Bawa P, McCollum BL, Wilder-Romans K, Apel IJ, Cao X, Speers C, Wang S, Chinnaiyan AM. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. Neoplasia. 2020;22:111\u20139. https:\/\/doi.org\/10.1016\/j.neo.2019.12.003.","journal-title":"Neoplasia"},{"key":"411_CR41","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","volume":"4","author":"X Sun","year":"2019","unstructured":"Sun X, Gao H, Yang Y, He M, Wu Y, Song Y, Tong Y, Rao Y. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019;4:64. https:\/\/doi.org\/10.1038\/s41392-019-0101-6.","journal-title":"Signal Transduct Target Ther"},{"key":"411_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cbf.3369","volume":"37","author":"Y Zou","year":"2019","unstructured":"Zou Y, Ma D, Wang Y. The PROTAC technology in drug development. Cell Biochem Funct. 2019;37:21\u201330. https:\/\/doi.org\/10.1002\/cbf.3369.","journal-title":"Cell Biochem Funct"},{"key":"411_CR43","doi-asserted-by":"publisher","first-page":"492","DOI":"10.3389\/fendo.2018.00492","volume":"9","author":"P Giovannelli","year":"2018","unstructured":"Giovannelli P, Di Donato M, Galasso G, Di Zazzo E, Bilancio A, Migliaccio A. The androgen receptor in breast cancer. Front Endocrinol. 2018;9:492. https:\/\/doi.org\/10.3389\/fendo.2018.00492.","journal-title":"Front Endocrinol"},{"key":"411_CR44","doi-asserted-by":"publisher","first-page":"106793","DOI":"10.1016\/j.ejps.2024.106793","volume":"198","author":"Z Wang","year":"2024","unstructured":"Wang Z, Che S, Yu Z. PROTAC: novel degradable approach for different targets to treat breast cancer. Eur J Pharm Sci. 2024;198:106793. https:\/\/doi.org\/10.1016\/j.ejps.2024.106793.","journal-title":"Eur J Pharm Sci"},{"key":"411_CR45","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.2217\/fon-2023-1180","volume":"20","author":"EP Hamilton","year":"2024","unstructured":"Hamilton EP, Ma CX, De Laurentiis M, Iwata H, Hurvitz SA. VERITAC-2: a phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+\/HER2\u2009\u2013\u2009advanced breast cancer. Future Oncol. 2024;20:1201\u201310. https:\/\/doi.org\/10.2217\/fon-2023-1180.","journal-title":"Future Oncol"},{"key":"411_CR46","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.neo.2020.07.002","volume":"22","author":"L Zhao","year":"2020","unstructured":"Zhao L, Han X, Lu J, McEachern D, Wang S. A highly potent PROTAC androgen receptor degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo. Neoplasia. 2020;22:522\u201332. https:\/\/doi.org\/10.1016\/j.neo.2020.07.002.","journal-title":"Neoplasia"},{"key":"411_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.60079\/ahr.v2i1.370","volume":"2","author":"A Asrina","year":"2024","unstructured":"Asrina A. Precision medicine approaches in oncology: current trends and future directions. AHR. 2024;2:36\u201348. https:\/\/doi.org\/10.60079\/ahr.v2i1.370.","journal-title":"AHR"},{"key":"411_CR48","doi-asserted-by":"publisher","first-page":"891580","DOI":"10.3389\/fonc.2022.891580","volume":"12","author":"GL Rampioni Vinciguerra","year":"2022","unstructured":"Rampioni Vinciguerra GL, Sonego M, Segatto I, Dall\u2019Acqua A, Vecchione A, Baldassarre G, Belletti B. CDK4\/6 inhibitors in combination therapies: better in company than alone: a mini review. Front Oncol. 2022;12:891580. https:\/\/doi.org\/10.3389\/fonc.2022.891580.","journal-title":"Front Oncol"},{"key":"411_CR49","doi-asserted-by":"publisher","first-page":"e26343","DOI":"10.1371\/journal.pone.0026343","volume":"6","author":"S Yang","year":"2011","unstructured":"Yang S, Xiao X, Meng X, Leslie KK. A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS ONE. 2011;6:e26343. https:\/\/doi.org\/10.1371\/journal.pone.0026343.","journal-title":"PLoS ONE"},{"key":"411_CR50","doi-asserted-by":"crossref","unstructured":"Badhe P. Unveiling ESR1\u2019s network centrality through multi-omics fusion and AI: implications for next-generation endocrine therapies. Preprints. (2025). https:\/\/www.preprints.org\/manuscript\/202510.0629\/v1","DOI":"10.20944\/preprints202510.0629.v1"},{"key":"411_CR51","doi-asserted-by":"publisher","unstructured":"Ishino, S., Ishino, Y.: DNA polymerases as useful reagents for biotechnology \u00e2\u20ac\u201c the history of developmental research in the field. Front. Microbiol. 5, (2014) https:\/\/doi.org\/10.3389\/fmicb.2014.00465","DOI":"10.3389\/fmicb.2014.00465"},{"key":"411_CR52","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.3390\/cancers16122259","volume":"16","author":"IM Browne","year":"2024","unstructured":"Browne IM, Okines AFC. Resistance to targeted inhibitors of the PI3K\/AKT\/mTOR pathway in advanced oestrogen-receptor-positive breast cancer. Cancers. 2024;16:2259. https:\/\/doi.org\/10.3390\/cancers16122259","journal-title":"Cancers"},{"key":"411_CR53","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.3390\/cancers13163943","volume":"13","author":"F Rascio","year":"2021","unstructured":"Rascio F, Spadaccino F, Rocchetti MT, Castellano G, Stallone G, Netti GS, Ranieri E. The pathogenic role of PI3K\/AKT pathway in cancer onset and drug resistance: an updated review. Cancers. 2021;13:3949. . https:\/\/doi.org\/10.3390\/cancers13163943","journal-title":"Cancers"},{"key":"411_CR54","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10555-016-9637-x","volume":"35","author":"A Guerrero-Zotano","year":"2016","unstructured":"Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K\/AKT\/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35:515\u201324. . https:\/\/doi.org\/10.1007\/s10555-016-9637-x","journal-title":"Cancer Metastasis Rev"},{"key":"411_CR55","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.1007\/s11033-020-05435-1","volume":"47","author":"N Jiang","year":"2020","unstructured":"Jiang N, Dai Q, Su X, Fu J, Feng X, Peng J. Role of PI3K\/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 2020;47:4587\u2013629. . https:\/\/doi.org\/10.1007\/s11033-020-05435-1","journal-title":"Mol Biol Rep"},{"key":"411_CR56","doi-asserted-by":"publisher","first-page":"102861","DOI":"10.1016\/j.ctrv.2024.102861","volume":"132","author":"C Hao","year":"2025","unstructured":"Hao C, Wei Y, Meng W, Zhang J, Yang X. PI3K\/AKT\/mTOR inhibitors for hormone receptor-positive advanced breast cancer. Cancer Treat Rev. 2025;132:102861. . https:\/\/doi.org\/10.1016\/j.ctrv.2024.102861","journal-title":"Cancer Treat Rev"},{"key":"411_CR57","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3892\/ijo.2015.3307","volume":"48","author":"GM Nitulescu","year":"2016","unstructured":"Nitulescu GM, Margina D, Juzenas P, Peng Q, Olaru OT, Saloustros E, Fenga C, Spandidos DA, Libra M, Tsatsakis AM. Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use. Int J Oncol. 2016;48:869\u201385. . https:\/\/doi.org\/10.3892\/ijo.2015.3307","journal-title":"Int J Oncol"},{"key":"411_CR58","doi-asserted-by":"publisher","first-page":"628690","DOI":"10.3389\/fphar.2021.628690","volume":"12","author":"C Dong","year":"2021","unstructured":"Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol. 2021;12:628690. . https:\/\/doi.org\/10.3389\/fphar.2021.628690","journal-title":"Front Pharmacol"},{"key":"411_CR59","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520\u20139. . https:\/\/doi.org\/10.1056\/NEJMoa1109653","journal-title":"N Engl J Med"},{"key":"411_CR60","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","volume":"391","author":"NC Turner","year":"2024","unstructured":"Turner NC, Im S-A, Saura C, Juric D, Loibl S, Kalinsky K, Schmid P, Loi S, Sunpaweravong P, Musolino A, Li H, Zhang Q, Nowecki Z, Leung R, Thanopoulou E, Shankar N, Lei G, Stout TJ, Hutchinson KE, Schutzman JL, Song C, Jhaveri KL. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med. 2024;391:1584\u201396. . https:\/\/doi.org\/10.1056\/NEJMoa2404625","journal-title":"N Engl J Med"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00411-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-026-00411-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-026-00411-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:19:47Z","timestamp":1789996787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-026-00411-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["411"],"URL":"https:\/\/doi.org\/10.1186\/s43046-026-00411-5","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"74"}}